Q2 2024 Earnings Forecast for scPharmaceuticals Inc. Issued By Leerink Partnrs (NASDAQ:SCPH)

scPharmaceuticals Inc. (NASDAQ:SCPH) – Analysts at Leerink Partnrs decreased their Q2 2024 earnings per share estimates for shares of scPharmaceuticals in a research report issued on Monday, August 12th. Leerink Partnrs analyst R. Ruiz now anticipates that the company will post earnings per share of ($0.47) for the quarter, down from their previous forecast of ($0.42). The consensus estimate for scPharmaceuticals’ current full-year earnings is ($1.46) per share. Leerink Partnrs also issued estimates for scPharmaceuticals’ Q3 2024 earnings at ($0.34) EPS, Q4 2024 earnings at ($0.25) EPS, FY2024 earnings at ($1.42) EPS, FY2025 earnings at ($0.90) EPS, FY2026 earnings at $0.55 EPS and FY2027 earnings at $2.40 EPS.

scPharmaceuticals (NASDAQ:SCPH) last announced its earnings results on Tuesday, May 14th. The company reported ($0.36) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.09. scPharmaceuticals had a negative return on equity of 132.39% and a negative net margin of 327.29%. The firm had revenue of $6.10 million for the quarter, compared to analysts’ expectations of $6.50 million. During the same quarter in the previous year, the company earned ($0.30) earnings per share.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $18.00 target price on shares of scPharmaceuticals in a report on Wednesday, May 15th.

scPharmaceuticals Stock Up 2.6 %

SCPH opened at $5.19 on Thursday. The company has a debt-to-equity ratio of 1.60, a quick ratio of 5.44 and a current ratio of 6.21. The company has a market capitalization of $187.12 million, a PE ratio of -3.51 and a beta of 0.11. The stock’s fifty day moving average is $4.43 and its 200-day moving average is $4.77. scPharmaceuticals has a one year low of $3.24 and a one year high of $8.05.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Thomasville National Bank raised its holdings in shares of scPharmaceuticals by 11.5% during the 1st quarter. Thomasville National Bank now owns 36,800 shares of the company’s stock valued at $185,000 after purchasing an additional 3,800 shares in the last quarter. Balanced Rock Investment Advisors LLC increased its position in scPharmaceuticals by 9.2% during the first quarter. Balanced Rock Investment Advisors LLC now owns 57,248 shares of the company’s stock worth $287,000 after buying an additional 4,827 shares during the last quarter. Raymond James & Associates raised its holdings in scPharmaceuticals by 6.6% during the fourth quarter. Raymond James & Associates now owns 87,049 shares of the company’s stock valued at $546,000 after buying an additional 5,377 shares in the last quarter. Perkins Capital Management Inc. acquired a new stake in shares of scPharmaceuticals in the first quarter worth about $53,000. Finally, Bank of New York Mellon Corp boosted its stake in shares of scPharmaceuticals by 15.1% during the 2nd quarter. Bank of New York Mellon Corp now owns 86,101 shares of the company’s stock worth $375,000 after acquiring an additional 11,269 shares in the last quarter. Hedge funds and other institutional investors own 89.52% of the company’s stock.

About scPharmaceuticals

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.